15.76 0.00 (0.00%)
After hours: 5:05PM EST
|Bid||15.00 x 4000|
|Ask||15.70 x 800|
|Day's Range||14.76 - 16.19|
|52 Week Range||13.09 - 30.00|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||31.67|
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be remiss not to mention that insider sales have Read More...
Gilead Sciences shares posted gains on Thursday morning after Bistrol-Myers' acquisition of Celgene sent shares across the sector higher.
CAMBRIDGE, Mass., Jan. 03, 2019 -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in.
Gilead Sciences (GILD) collaborates with Scholar Rock Holding Corporation for the development of fibrotic disease candidates.
Gilead Sciences, Inc. (NASDAQ: GILD ) announced a strategic collaboration Wednesday with Scholar Rock Holding Corp (NASDAQ: SRRK ). Although not strictly a nonalcoholic steatohepatitis, or NASH, deal, ...
Gilead Sciences, Inc. (GILD) and Scholar Rock Holding Corporation (SRRK) announced today that the companies have entered into a strategic collaboration to discover and develop highly specific inhibitors of transforming growth factor beta (TGFβ) activation for the treatment of fibrotic diseases. Under the collaboration, Gilead has exclusive options to license worldwide rights to product candidates that emerge from three Scholar Rock TGFβ programs: inhibitors that target activation of latent TGFβ1 with high affinity and specificity, inhibitors that selectively target activation of latent TGFβ1 localized to extracellular matrix, and a third TGFβ discovery program. Scholar Rock is responsible for antibody discovery and preclinical research through product candidate nomination, after which, upon exercising the option for a program, Gilead will be responsible for the program’s preclinical and clinical development and commercialization.
Scholar Rock Holding Corporation (SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the European Medicines Agency’s (EMA’s) Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending SRK-015 (human anti-promyostatin monoclonal antibody) for designation as an orphan medicinal product for the treatment of Spinal Muscular Atrophy (SMA). SRK-015 was previously granted orphan drug designation by the U.S. Food and Drug Administration (FDA) in March 2018. Orphan Medicinal Product Designation by the European Commission is available to companies developing products intended to treat a life-threatening or chronically debilitating condition that affects fewer than five in 10,000 people in the EU, and has the potential to be of significant benefit. This designation could allow for a number of incentives, including protocol assistance, access to the centralized authorization procedure, reduced regulatory fees, and a 10-year period of marketing exclusivity in the EU after product approval.
CAMBRIDGE, Mass., Nov. 27, 2018 -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in.
Scholar Rock Holding Corporation (SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that Edward (Ted) Myles, a financial and operational leader with deep experience across the biotechnology and pharmaceutical industries, has been appointed to the Company’s Board of Directors. Mr. Myles will serve as chair of the Company’s audit committee and as a member of the compensation committee.
Preclinical Data Presented at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting Shows Highly Specific Inhibitor of TGFβ1, SRTβ1-Ab3, Renders Resistant Solid Tumors.
Scholar Rock (SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will present at the Jefferies London Healthcare Conference on Wednesday, November 14, 2018 at 4:40 p.m. GMT / 11:40 a.m. EST. A live webcast of the presentation may be accessed by visiting the Investors & Media section of the Scholar Rock website at http://investors.scholarrock.com. An archived replay of the webcast will be available on the Company’s website for approximately 90 days following the presentation.
RANDOR, PA / ACCESSWIRE / June 21, 2018 / Kaskela Law LLC is investigating Scholar Rock Holding Corp. ("Scholar Rock" or the "Company") (NASDAQ: SRRK) on behalf of the Company's stockholders. ...
As Scholar Rock Holding Corp (NASDAQ: SRRK )’s IPO quiet period expired Monday, four analysts came out with bullish recommendations on the stock. Here’s what one of them had to say. The Rating BMO Capital ...
In this article, I’m going to take a look at Scholar Rock Holding Corporation’s (NASDAQ:SRRK) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subjectRead More...